This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 29/1/12    most recent ATVBAHA.108.168757v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dol-Gleizes, F. Articles by Bono, F. Search for Related Content PubMed PubMed Citation Articles by Dol-Gleizes, F. Articles by Bono, F. Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:12.)
© 2009 American Heart Association, Inc.

Integrative Physiology/Experimental Medicine

Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice

Frédérique Dol-Gleizes; Réjane Paumelle; Virgile Visentin; Anne-Marie Marés; Perrine Desitter; Nathalie Hennuyer; Andries Gilde; Bart Staels; Paul Schaeffer; Françoise Bono

From Sanofi-Aventis R&D (F.D.-G., V.V., A.-M.M., P.S., F.B.), Toulouse, France; and Institut Pasteur de Lille, Département d’Athérosclérose (R.P., P.D., N.H., A.G., B.S.), INSERM U545,Université de Lille 2, Faculté de Pharmacie et de Médecine, Lille, France.

Correspondence to Françoise Bono, Sanofi-Aventis Recherche & Développement, Thrombosis & Angiogenesis Department, 195, Route d’Espagne, BP 13669, F-31036 Toulouse Cedex 1, France. E-mail francoise.bono{at}sanofi-aventis.com

Objective— The objective of this study was to determine whether the potent selective cannabinoid receptor-1 antagonist rimonabant has antiatherosclerotic properties.

Methods and Results— Rimonabant (50 mg/kg/d in the diet) significantly reduced food intake (from 3.35±.04 to 2.80±0.03 g/d), weight gain (from 14.6±0.7 g to –0.6±0.3 g), serum total cholesterol (from 8.39±0.54 to 5.32±0.18 g/L), and atherosclerotic lesion development in the aorta (from 1.7±0.22 to 0.21±0.037 mm²) and aortic sinus (from 101 000±7800 to 27 000±2900 µm²) of LDLR^–/– mice fed a Western-type diet for 3 months. Rimonabant also reduced plasma levels of the proinflammatory cytokines MCP-1 and IL12 by 85% (P<0.05) and 76% (P<0.05), respectively. Pair-fed animals had reduced weight gain (6.2±0.6 g gain), but developed atherosclerotic lesions which were as large as those of untreated animals, showing that the antiatherosclerotic effect of rimonabant is not related to reduced food intake. Interestingly, rimonabant at a lower dose (30 mg/kg/d in the diet) reduced atherosclerosis development in the aortic sinus (from 121 000±20 000 to 62 000±11 000 µm², 49% reduction, P<0.05), without affecting serum total cholesterol (7.8±0.7 g/L versus 8.1±1.3 g/L in the control group). Rimonabant decreased lipopolysaccharide (LPS)- and IL1β-induced proinflammatory gene expression in mouse peritoneal macrophages in vitro as well as thioglycollate-induced recruitment of macrophages in vivo (10 mg/kg, po bolus).

Conclusions— These results show that rimonabant has antiatherosclerotic effects in LDLR^–/– mice. These effects are partly unrelated to serum cholesterol modulation and could be related to an antiinflammatory effect.

Rimonabant (30 mg/kg/d in the diet) significantly reduced atherosclerotic lesion size in the aortic sinus of Western diet–fed LDLR-deficient mice without affecting serum cholesterol levels, whereas higher doses strongly decreased serum cholesterol and atherosclerosis. Rimonabant also reduced thioglycollate-induced recruitment of macrophages in vivo. These results show that rimonabant has antiatherosclerotic effects in LDLR^–/– mice partly related to an antiinflammatory effect.

Key Words: atherosclerosis • rimonabant • obesity • LDLR-deficient mice

Related Article:

Cannabinoid CB₁ Receptor Antagonists for Atherosclerosis and Cardiometabolic Disorders: New Hopes, Old Concerns?

Pál Pacher
Arterioscler Thromb Vasc Biol 2009 29: 7-9. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				S. Immenschuh Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work? Cardiovasc Res, October 29, 2009; (2009) cvp339v2. [Full Text] [PDF]

				K. H. Han, S. Lim, J. Ryu, C.-W. Lee, Y. Kim, J.-H. Kang, S.-S. Kang, Y. K. Ahn, C.-S. Park, and J. J. Kim CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages Cardiovasc Res, September 25, 2009; (2009) cvp240v3. [Abstract] [Full Text] [PDF]

				M.-R. Taskinen ADAGIO-Lipids Gives Promises but Faces the Setbacks Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 339 - 340. [Full Text] [PDF]

				P. Pacher Cannabinoid CB1 Receptor Antagonists for Atherosclerosis and Cardiometabolic Disorders: New Hopes, Old Concerns? Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 7 - 9. [Full Text] [PDF]